1616262-57-7

Upstream product

• 1314395-91-9 (±)-benzyl 2-methyl-5-oxopiperidine-1-carboxylate 
• 1431473-24-3 (2R,5S)-benzyl 5-hydroxy-2-methylpiperidine-1-carboxylate 
• 1431473-03-8 benzyl (2R,5R)-2-methyl-5-{[(4-nitrophenyl)carbonyl]oxy}piperidine-1-carboxylate 
• 1431473-04-9 benzyl (2R,5R)-5-hydroxy-2-methylpiperidine-1-carboxylate 
• 58481-11-1 methyl 2-chloroisonicotinate 
• 1222491-34-0 (2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-hydroxy-2-methylpiperidin-1-yl)methanone 
• 137688-20-1 (R)-2-(but-3-en-1-yl)oxirane 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 285995-17-7 (R)-2-Hydroxy-(R)-5-methylpiperidine-(R)-amine-N-oxide 
• 774238-83-4 2-fluoro-N-methyl-N-(methyloxy)-4-pyridinecarboxamide 
• 402-65-3 2-fluoropyridine-4-carboxylic acid 

Relevant academic research and scientific papers

HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric dis

2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.